By Improving Sleep, TNX-102 SL Reduces Pain and Fatigue in Fibromyalgia
Key Takeaways TNX-102 SL significantly improved pain, sleep, fatigue, and functioning in fibromyalgia patients, meeting primary and secondary endpoints in a phase 3 trial. The FDA approved TNX-102 SL in 2025, marking the first new fibromyalgia treatment in over 15 years and the fourth overall. Investigators evaluated whether targeting sleep-related neurophysiology with bedtime TNX-102 SL…